Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.30 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6582228 | 0.77 | — | — | |
| SCHEMBL4638992 | 0.77 | IP6K1 (0.30) | IP6K1IP6K3IP6K2 | |
| SCHEMBL4638995 | 0.77 | IP6K1 (0.30) | IP6K1IP6K3IP6K2 | |
| SCHEMBL14035312 | 0.76 | — | — | |
| SCHEMBL14035315 | 0.74 | — | — | |
| SCHEMBL4639104 | 0.72 | IP6K1 (0.33) | IP6K1IP6K3IP6K2 | |
| SCHEMBL16706982 | 0.72 | ESR1 (0.35) | IP6K1IP6K3IP6K2 | |
| Povafonidine SCHEMBL21771336 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL4639205 | 0.68 | ADRA2A (0.47) | — | |
| SCHEMBL6581921 | 0.68 | IP6K1 (0.30) | IP6K1IP6K3IP6K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015073736-A1 | METHODS AND COMPOSITIONS FOR TREATING ADHD | ARBOR PHARMACEUTICALS, LLC (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150133516-A1 | Methods and Compositions for Treating ADHD | ARBOR PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| EP-1594862-B1 | METHODS OF MAKING 6-[ (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-] -7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | UNIV NEBRASKA (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133516-A1 | Methods and Compositions for Treating ADHD | ADRA2C, ADRA2A, ADRB2 | IP6K1 2880/4885IP6K3 2385/4885IP6K2 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.